We have reason to believe that radiopharmaceutical companies are positioned for increased investment due to significant advancements in the sector that are currently being overshadowed by antibody-drug conjugates (ADCs, which we previously covered here in April).
Radiopharmaceuticals, which use a radioactive compound combined with a targeting molecule t…